ArticleJournal of virology2001
Serum and mucosal immune responses to an inactivated influenza virus vaccine induced by epidermal powder immunization.
Article in Journal of virology, 2001. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 68 citations in OpenAlex.
- Modulation of systemic and mucosal immunity against an inactivated vaccine of Newcastle disease virus by oral co-administration of live attenuated Salmonella enterica serovar Typhimurium expressing chicken interleukin-18 and interferon-α.The Journal of veterinary medical science · 2015Trial
- Contrasting effects of type I interferon as a mucosal adjuvant for influenza vaccine in mice and humans.Vaccine · 2009Trial
- Article
- Development of thermostable vaccine adjuvants.Expert review of vaccines · 2021Review
- Salivary anti-SARS-CoV-2 IgA as an accessible biomarker of mucosal immunity against COVID-19.medRxiv : the preprint server for health sciences · 2020Article
- Green tea cultivar 'Benifuuki' potentiates split vaccine-induced immunoglobulin A production.Journal of natural medicines · 2017Article
- Induction of mucosal immunity through systemic immunization: Phantom or reality?Human vaccines & immunotherapeutics · 2016Article
- Combined Oral and Intravenous Immunization Stimulates Strong IgA Responses in Both Systemic and Mucosal Compartments.PloS one · 2016Article
- Lung CD8+ T Cell Impairment Occurs during Human Metapneumovirus Infection despite Virus-Like Particle Induction of Functional CD8+ T Cells.Journal of virology · 2015Article
- Multi-scale modeling for the transmission of influenza and the evaluation of interventions toward it.Scientific reports · 2015Article
- Microneedle and mucosal delivery of influenza vaccines.Expert review of vaccines · 2012Review
- Article
- Article
- Micro-scale devices for transdermal drug delivery.International journal of pharmaceutics · 2008Review
- Development of stable influenza vaccine powder formulations: challenges and possibilities.Pharmaceutical research · 2008Review
- Immunization without needles.Nature reviews. Immunology · 2005Review
- Review
- Plasmid vectors encoding cholera toxin or the heat-labile enterotoxin from Escherichia coli are strong adjuvants for DNA vaccines.Journal of virology · 2002Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Both circulating and mucosal antibodies are considered important for protection against infection by influenza virus in humans and animals. However, current inactivated vaccines administered by intramuscular injection using a syringe and needle elicit primarily circulating antibodies. In this study, we report that epidermal powder immunization (EPI) via a unique powder delivery system elicits both serum and mucosal antibodies to an inactivated influenza virus vaccine. Serum antibody responses to influenza vaccine following EPI were enhanced by codelivery of cholera toxin (CT), a synthetic oligodeoxynucleotide containing immunostimulatory CpG motifs (CpG DNA), or the combination of these two adjuvants. In addition, secretory immunoglobulin A (sIgA) antibodies were detected in the saliva and mucosal lavages of the small intestine, trachea, and vaginal tract, although the titers were much lower than the IgG titers. The local origin of the sIgA antibodies was further shown by measuring antibodies released from cultured tracheal and small intestinal fragments and by detecting antigen-specific IgA-secreting cells in the lamina propria using ELISPOT assays. EPI with a single dose of influenza vaccine containing CT or CT and CpG DNA conferred complete protection against lethal challenges with an influenza virus isolated 30 years ago, whereas a prime and boost immunizations were required for protection in the absence of an adjuvant. The ability to elicit augmented circulating antibody and mucosal antibody responses makes EPI a promising alternative to needle injection for administering vaccines against influenza and other diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.